BIOASIS TECHNOLOGIES INC. a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it has retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services.
Kilmer Lucas combines a healthcare industry focus with a global reach. Working directly from its offices in Toronto, New York and San Francisco, and through a carefully assembled affiliate network that includes seasoned professionals based in Israel, Asia and Europe, Kilmer Lucas helps its clients to successfully navigate and penetrate the capital markets and media both at home and abroad. More information about the firm can be found at www.kilmerlucas.com.
“As biOasis continues to move aggressively forward into its commercialization phase, we are confident that Kilmer Lucas is the right partner to help us communicate our progress to a broader investor audience,” said Rob Hutchison, biOasis’ CEO.
Stephen Kilmer, President of Kilmer Lucas, commented, “We believe that a strong investment story is emerging at biOasis and we are excited that the company has chosen us to help tell it. Through the provision of a full range of investor relations and financial communications services, our primary goals will be to assist biOasis in achieving a fair and sustainable market valuation and to enhance the reputation that the company carries in the minds of investors, analysts and members of the media.”
Under the terms of the agreement, BiOasis will pay Kilmer Lucas a monthly retainer fee of C$6,500 for its services. Should BiOasis uplist its common shares for trading to a national U.S. stock exchange while this agreement is in effect, the monthly retainer fee paid by it to Kilmer Lucas will automatically increase to US$7,500. The agreement, which commences immediately, has an initial term of 60 days. Following the end of the initial term, the agreement will renew automatically for 30-day periods unless terminated by either party.
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.
On Behalf of the Board of Directors
Rob Hutchison, Chairman & CEO
biOasis Technologies Inc.
Mr. Rob Hutchison
Investor & Media Contact:
Kilmer Lucas Inc.